Home | Cancer Immunology Research

Read the September issue!
About the cover: To study the effectiveness of mesothelin-specific engineered T cells in vivo, a mouse model was evaluated for resemblance to human HGSOC. Find out more in the article by Anderson, et al. Cover artwork by Lewis Long.
Cancer Immunology at the Crossroads
Read: Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer, Susan T. Yeyeodu, et al.
Research Article
Read: Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection, Xiang Yuan, et al.

From the Current Issue

What We're Reading

A Sampling of Highlights from the Literature

Cancer Immunol Res September 1 2019 7 (9) 1383-1383;
Research Articles

Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas

Michael Bockmayr, Frederick Klauschen, Cecile L. Maire, Stefan Rutkowski, Manfred Westphal, Katrin Lamszus, Ulrich Schüller and Malte Mohme

Cancer Immunol Res September 1 2019 7 (9) 1401-1411; DOI:10.1158/2326-6066.CIR-18-0939

Analysis of the immune phenotype of rare molecular subgroups in pediatric and adult high-grade gliomas provides information that may increase the efficacy of immunotherapeutic approaches for pediatric and adolescent high-grade gliomas.
Research Articles

Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression

Wenwen Xu, Juan Dong, Yongwei Zheng, Juan Zhou, Ying Yuan, Hieu Minh Ta, Halli E. Miller, Michael Olson, Kamalakannan Rajasekaran, Marc S. Ernstoff, Demin Wang, Subramaniam Malarkannan and Li Wang

Cancer Immunol Res September 1 2019 7 (9) 1497-1510; DOI:10.1158/2326-6066.CIR-18-0489

VISTA is an immune-checkpoint protein that can regulate the functions of MDSCs and DC subsets. Myeloid cell activation precedes T cell-mediated antitumor responses and, thus, contributes to the antitumor mechanisms of VISTA inhibition.
Research Articles

SLAMF6 as a Regulator of Exhausted CD8⁺ T Cells in Cancer

Burcu Yigit, Ninghai Wang, Elisa ten Hacken, Shih-Shih Chen, Atul K. Bhan, Abel Suarez-Fueyo, Eri Katsuyama, George C. Tsokos, Nicholas Chiorazzi, Catherine J. Wu, Jan A. Burger, Roland W. Herzog, Pablo Engel and Cox Terhorst

Cancer Immunol Res September 1 2019 7 (9) 1485-1496; DOI:10.1158/2326-6066.CIR-18-0664

SLAMF6 can be a target for modulating T-cell exhaustion. These data highlight the potential of targeting SLAMF6, either with single agents or in combination with other inhibitors, to unleash CD8⁺ T-cell responses to improve immunotherapy efficacy.

Main menu

User menu

Search

From the Current Issue

OnlineFirst Articles

Articles

Info for

About Cancer Immunology Research